NW
VRTX icon

NewEdge Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

NewEdge Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.37M Buy
9,788
+1,386
+16% +$646K 0.05% 243
2025
Q4 		$3.81M Buy
8,402
+2,754
+49% +$1.19M 0.04% 298
2025
Q3 		$2.36M Sell
5,648
-1,970
-26% -$823K 0.03% 357
2025
Q2 		$2.86M Sell
7,618
-1,690
-18% -$779K 0.04% 307
2025
Q1 		$4.51M Sell
9,308
-32,139
-78% -$15M 0.08% 197
2024
Q4 		$16.7M Buy
41,447
+1,297
+3% +$601K 0.29% 89
2024
Q3 		$18.7M Buy
40,150
+1,238
+3% +$595K 0.34% 77
2024
Q2 		$18.2M Buy
38,912
+4,245
+12% +$1.84M 0.4% 69
2024
Q1 		$13.9M Buy
34,667
+4,095
+13% +$1.73M 0.31% 88
2023
Q4 		$12.4M Buy
30,572
+3,478
+13% +$1.28M 0.32% 86
2023
Q3 		$9.42M Buy
27,094
+6,275
+30% +$2.19M 0.3% 94
2023
Q2 		$7.33M Buy
20,819
+206
+1% +$69.4K 0.24% 105
2023
Q1 		$6.49M Buy
20,613
+235
+1% +$70.5K 0.25% 99
2022
Q4 		$5.88M Buy
20,378
+17
+0.1% +$5.18K 0.25% 97
2022
Q3 		$5.89M Buy
20,361
+16,361
+409% +$4.71M 0.28% 93
2022
Q2 		$1.13M Buy
4,000
+1,632
+69% +$437K 0.05% 275
2022
Q1 		$618K Buy
+2,368
New +$562K 0.03% 275

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NewEdge Wealth's VRTX Position: Q1 2026 in Review

NewEdge Wealth increased its Vertex Pharmaceuticals (VRTX) stake by 16% in Q1 2026, buying an estimated $646K and bringing the position to 9,788 shares worth $4.37M. The position accounts for 0.05% of the portfolio, ranked #243.

NewEdge Wealth first reported a position in VRTX in Q1 2022 and has held it in 17 quarters since. The position peaked at $18.7M in Q3 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • NewEdge Wealth held 9,788 shares of Vertex Pharmaceuticals worth $4.37M as of Q1 2026.
  • NewEdge Wealth bought 1,386 Vertex Pharmaceuticals shares in Q1 2026, an estimated $646K.
  • Vertex Pharmaceuticals made up 0.05% of NewEdge Wealth's portfolio in Q1 2026, its #243 holding.
  • NewEdge Wealth first reported a position in Vertex Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
  • NewEdge Wealth's Vertex Pharmaceuticals position peaked at $18.7M in Q3 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on NewEdge Wealth's 13F filing for Q1 2026, filed 13 May 2026.